Kamada KMDA
NASDAQ KMDA
$8.21 -0.08 (-0.97%)
As of: Sep 9, 2026 · 3:59 PM EDT

Kamada (KMDA) Change in Receivables (2012 - 2026)

Kamada's (KMDA) quarterly Change in Receivables came in at -$191000.0 in Q2 2026, up 90.96% on a YoY basis from -$100020.6 in Q2 2025, and up 98.04% quarter-over-quarter from -$9.8 million in Q1 2026.

Analysis

Kamada (KMDA) Change in Receivables (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Change in Receivables for 15 consecutive years, with -$191000.0 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Change in Receivables rose 90.96% year-over-year to -$191000.0; the trailing twelve-month figure through Jun 2026 stood at -$6.7 million (down 71.76% YoY), and the FY2025 full-year result was -$5.4 million, down 173.5% from the prior year.
  • Change in Receivables grew to -$191000.0 in Q2 2026 per KMDA's latest filing, from -$9.8 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $10.0 million in Q3 2024 and bottomed at -$9.8 million in Q1 2026.
  • Historically, Change in Receivables has averaged -$611666.7 across 5 years, with a median of -$404500.0 in 2023.
  • The widest YoY moves for Change in Receivables: up 1718.77% in 2024, down 4261.02% in 2024.
  • Over 5 years, Change in Receivables stood at -$3.1 million in 2022, then surged by 283.29% to $5.8 million in 2023, then sank by 190.78% to -$5.2 million in 2024, then jumped by 182.24% to $4.3 million in 2025, then tumbled by 104.44% to -$191000.0 in 2026.
  • According to Business Quant data, Change in Receivables over the past three periods registered -$191000.0, -$9.8 million, and $4.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 1.09 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 333.00 Mn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 140.20 Mn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 838.50 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -53.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 31.60 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 269.40 Mn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 Kamada 473.57 Mn 403.43 Mn 22.47 Mn -191,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -191,000.00
Mar 31, 2026 -9.76 Mn
Dec 31, 2025 4.30 Mn
Sep 30, 2025 -1.04 Mn
Jun 30, 2025 -2.11 Mn
Mar 31, 2025 -6.56 Mn
Dec 31, 2024 -5.23 Mn
Sep 30, 2024 10.00 Mn
Jun 30, 2024 -7.37 Mn
Mar 31, 2024 610,000.00
Dec 31, 2023 5.76 Mn
Sep 30, 2023 -618,000.00
Jun 30, 2023 177,000.00
Mar 31, 2023 6.31 Mn
Dec 31, 2022 -3.14 Mn
Sep 30, 2022 -6.36 Mn
Jun 30, 2022 3.61 Mn
Mar 31, 2022 589,000.00
Dec 31, 2021 -8.42 Mn
Sep 30, 2021 1.20 Mn